Contraception & Sterilization Flashcards
Hormonal contraceptives provide the most reversible contraception. What are the options?
OCPs
Injectables (DepoProvera)
Implantable (Nexplanon)
Hormone-containing IUDs (Mirena, Skyla, Liletta, Kyleena)
Contraceptive patches (OrthoEvra)
Contraceptive rings (Nuvaring)
MOA of combination OCPs
Suppression of hypothalamic GnRH with subsequent suppression of pituitary production of FSH and LH
The progesterone component is the major player — suppresses LH and therefore ovulation, as well as thickening cervical mucous
The estrogen component mainly improves cycle control by stabilizing the endometrium and allowing less breakthrough bleeding
MOA of progestin-only OCP
Primarily makes cervical mucous thick and impermeable
Ovulation continues in about 40% of users
In what pt populations are progestin-only OCPs used?
Breastfeeding women
Women with a contraindication to estrogen
Why must progestin-only OCPs be taken at the same time every day?
Because of the low dose — if pt is more than 3 hours late taking the pil then they should use a backup method for 48 hrs
Benefits of hormonal oral contraceptives
Menstrual cycle regularity
Improve dysmenorrhea
Decrease risk of iron deficiency anemia
Lower incidence of endometrial and ovarian cancers, benign breast, and ovarian disease (cysts)
Adverse effects of OCPs
Breakthrough bleeding (more likely in first 3 months, then it usually gets better)
Amenorrhea
Mild AEs include bloating, weight gain, breast tenderness, nausea, fatigue, headache
Serious AEs include venous thrombosis, pulmonary embolism, cholestasis and gallbladder disease, stroke and myocardial infarction, hepatic tumors
MOA of the OrthoEvra patch
Transdermal patch containing estrogen and progesterone — same effect as combination OCPs
In what pt populations should the patch be used with caution?
Women > 198 lbs
Those at risk of thrombosis
The patch as the same side effects and precautions as OCPs, except a greater risk of ______
Thrombosis
MOA of vaginal ring (nuvaring)
Combination estrogen and progesterone in ring inserted in vagina for 3 weeks, then removed for 1 week (greater compliance)
Can be removed for up to 3 hours without affecting efficacy
Why is the vaginal ring considered better tolerated than OCPs?
Not systemically absorbed through GI tract; also less breakthrough bleeding
What patient populations CANNOT use combination contraceptives?
Women >35 y/o who smoke cigarettes
Women with personal hx of thromboembolic event (pts with family hx need to be evaluated for inherited thrombophilia)
Women with hx of CAD, cerebral vascular disease, CHF, migraine with aura, uncontrolled HTN
Women with moderate to severe liver disease or liver tumors
Women with POORLY CONTROLLED diabetes, chronic HTN, systemic lupus erythematosus [may use if good control and adequate f/u]
The primary injectable hormonal contraceptive is an IM injection of depot medroxyprogesterone acetate every 11-13 weeks. This maintains contraceptive level of progestin for about 14 weeks. What is the MOA and efficacy?
Thickens cervical mucous, decidualization of the endometrium, blocks the LH surge and ovulation
Efficacy is roughly equivalent to that of sterilization and is not altered by weight
Black box warning associated with depo-provera
Alterations of bone metabolism d/t decreased estrogen levels — of particular concern in adolescents
If used for more than 2 years, should consider alternative method